AI Article Synopsis

  • Hidradenitis suppurativa (HS) is a complex skin condition that's tough to treat, with adalimumab being the only approved therapy and only helping about 50% of patients.
  • The study investigated differences in gene expression between affected (lesional) and unaffected (nonlesional) skin in HS patients before and after 12 weeks of adalimumab treatment, aiming to uncover potential biomarkers for treatment response.
  • Findings suggest significant immune system involvement in HS, with certain genes indicating treatment response and disease severity, pointing towards the need for personalized treatment strategies targeting specific immune pathways.

Article Abstract

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with significant morbidity. The pathogenesis remains incompletely understood although immune dysregulation plays an important role. It is challenging to treat and approximately 50% of patients respond clinically to adalimumab, the only licensed treatment.

Objectives: To examine differences between lesional and nonlesional HS skin at baseline using bulk RNA sequencing, and to compare the transcriptome in the skin before and after 12 weeks of treatment with adalimumab. To examine transcriptomic differences between adalimumab responders and nonresponders using Hidradenitis Suppurativa Clinical Response and the International Hidradenitis Suppurativa Severity Score System (IHS4); and to compare transcriptomic differences based on disease severity (Hurley stage and IHS4).

Methods: We completed bulk RNA sequencing on lesional and nonlesional skin samples of patients before and after 12 weeks of treatment with adalimumab.

Results: Baseline differentially expressed genes and pathways between lesional and nonlesional skin highlighted chemokines and antimicrobial peptides produced by keratinocytes; B-cell function; T-cell-receptor, interleukin-17 and nuclear factor-κB signalling; and T-helper-cell differentiation. Transcriptomic differences were identified in lesional skin at baseline, between subsequent responders and nonresponders. Patients with severe HS who did not respond to adalimumab had enriched complement and B-cell activation pathways at baseline. In addition, logistic regression identified CCL28 in baseline lesional HS skin as a potential biomarker of treatment response.

Conclusions: This highlights the potential for targeting B-cell and complement pathways in HS treatment and the potential of stratifying patients at baseline to the most suitable treatment based on the skin transcriptome. CCL28 has not previously been identified in HS skin and has potential clinical relevance due to its antimicrobial function and homing of B and T cells at epithelial surfaces. Our results provide data to inform future translational and clinical studies on therapeutics in HS.

Download full-text PDF

Source
http://dx.doi.org/10.1093/bjd/ljac007DOI Listing

Publication Analysis

Top Keywords

hidradenitis suppurativa
16
lesional nonlesional
12
nonlesional skin
12
transcriptomic differences
12
skin
9
b-cell complement
8
respond adalimumab
8
skin baseline
8
bulk rna
8
rna sequencing
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!